Growth Metrics

Eli Lilly (LLY) Acquisitions (2016 - 2022)

Eli Lilly filings provide 11 years of Acquisitions readings, the most recent being $327.2 million for Q4 2022.

  • On a quarterly basis, Acquisitions changed N/A to $327.2 million in Q4 2022 year-over-year; TTM through Dec 2022 was $327.2 million, a 56.22% decrease, with the full-year FY2022 number at $327.2 million, down 56.22% from a year prior.
  • Acquisitions hit $327.2 million in Q4 2022 for Eli Lilly, down from $747.4 million in the prior quarter.
  • In the past five years, Acquisitions ranged from a high of $6.9 billion in Q1 2019 to a low of $327.2 million in Q4 2022.
  • Median Acquisitions over the past 4 years was $798.3 million (2020), compared with a mean of $2.2 billion.
  • Biggest five-year swings in Acquisitions: plummeted 87.72% in 2020 and later decreased 12.0% in 2021.
  • Eli Lilly's Acquisitions stood at $6.9 billion in 2019, then plummeted by 87.72% to $849.3 million in 2020, then dropped by 12.0% to $747.4 million in 2021, then crashed by 56.22% to $327.2 million in 2022.
  • The last three reported values for Acquisitions were $327.2 million (Q4 2022), $747.4 million (Q1 2021), and $849.3 million (Q1 2020) per Business Quant data.